A neutralizing monoclonal antibody previously mapped exclusively on human immunodeficiency virus type 1 gp41 recognizes an epitope in p17 sharing the core sequence IEEE

Journal of Virology

Volumn 71, Issue 3, 1997, Pages 2457-2462

  Buratti, Emanuele ^a   Tisminetzky, Sergio G ^a   D'Agaro, Piero ^b   Baralle, Francisco E ^a  

^a INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

^b INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; RECOMBINANT PROTEIN; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN;

ANIMAL CELL; ANTIGEN RECOGNITION; ARTICLE; CROSS REACTION; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; VIRUS NEUTRALIZATION;

EID: 0031047826     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.71.3.2457-2462.1997     Document Type: Article

References (29)

1. Abimiku, A. G., G. Franchini, J. Tartaglia, K. Aldrich, M. Myagkikh, P. D. Markham, P. Chong, M. Klein, M.-P. Kieny, E. Paoletti, R. C. Gallo, and M. Robert-Guroff. 1995. HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques. Nat. Med. 1:321-329.
2. Achour, A., O. Picard, D. Zagury, P. S. Sarin, R. C. Gallo, P. H. Naylor, and A. L. Goldstein. 1990. HGP-30, a synthetic analogue of human immunodeficiency virus (MIV) p17, is a target for cytotoxic lymphocytes in HIV-infected individuals. Proc. Natl. Acad. Sci. USA 87:7045-7049.
3. Binley, J. M., H. J. Ditzel, C. F. Barbas III, N. Sullivan, J. Sodroski, P. W. H. I. Parren, and D. R. Burton. 1996. Human antibody response to HIV 1 glycoprotein 41 cloned in phage display libraries suggest three major epitopes are recognized and give evidence for conserved antibody motifs in antigen binding. AIDS Res. Hum. Retroviruses 12:911-923.
4. Boucher, C. A., W. J. Krone, J. Goudsmit, R. H. Meloen, P. H. Naylor, A. L. Goldstein, D. K. Sun, and P. S. Sarin. 1990. Immune response and epitope mapping of a candidate HIV-1 p17 vaccine HGP30. J. Clin. Lab. Anal. 4:43-47.
5. Breuer, J., N. W. Douglas, N. Goldman, and R. S. Daniels. 1995. Human immunodeficiency virus type 2 (HIV-2) env gene analysis: prediction of glycoprotein epitopes important for heterotypic neutralization and evidence for three genotype clusters within the HTV-2a subtype. J. Gen. Virol. 76: 333-345.
6. Broliden, P.-A., A. Von Gegerfelt, P. Clapham, J. Rosen, E.-M. Fenyo, B. Wahren, and K. Broliden. 1992. Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins. Proc. Natl. Acad. Sci. USA 89:461-465.
7. Buratti, E., S. G. Tisminetzky, E. S. Scodeller, and F. E. Baralle. 1996. Conformational display of two neutralizing epitopes of HIV-1 gp41 on the Flock House Virus capsid protein. J. Immunol. Methods 197:7-18.
8. Chanh, T. C., G. R. Dreesman, P. Kanda, G. P. Linette, J. T. Sparrow, D. D. Ho, and R. C. Kennedy. 1986. Induction of anti-HIV neutralizing antibodies by synthetic peptides. EMBO J. 5:3065-3071.
9. Dalgleish, A. G., T. C. Chanh, R. C. Kennedy, P. Kanda, P. R. Clapham, and R. A. Weiss. 1988. Neutralization of diverse HIV-1 strains by monoclonal antibodies raised against a gp41 synthetic peptide. Virology 165:209-215.
10. Davis, D., B. Chaudhri, D. M. Stephens, C. A. Carne, C. Willers, and P. J. Lachmann. 1990. The immunodominance of epitopes within the transmembrane protein (gp41) of human immunodeficiency virus type 1 may be determined by the host's previous exposure to similar epitopes on unrelated antigens. J. Gen. Virol. 71:1975-1983.
11. Evans, D. J., J. McKeating, J. M. Meredith, K. L. Burke, K. Katrak, A. John, M. Ferguson, P. D. Minor, R. A. Weiss, and J. W. Almond. 1989. An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies. Nature 339:385-388.
12. Ho, D. D., J. A. McKeating, X. L. Li, T. Moudgil, E. S. Daar, N.-C. Sun, and J. E. Robinson. 1991. Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody. J. Virol. 65:489-493.
13. Kain, K. C., P. A. Orlandi, and D. E. Lanar. 1991. Universal promoter for gene expression without cloning: expression-PCR. BioTechniques 10:366-373.
14. Kennedy, R. C., R. D. Henkel, D. Pauletti, J. S. Allan, T. H. Lee, M. Essex, and G. R. Dreesman. 1986. Antiserum to a synthetic peptide recognises HTLV-III envelope glycoprotein. Science 231:1556-1559.
15. Levy, J. 1993. Pathogenesis of human immunodeficiency virus infection. Microbiol. Rev. 57:183-289.
16. Liu, X., A. Ota, M. Watanabe, S. Ueda, A. Saitoh, H. Shinagawa, A. Nakata, T. Kurimura, X. Wang, and Y. Zhao. 1995. Three antigenic regions in p17 of human immunodeficiency virus type 1 (HIV-1) revealed by mouse monoclonal antibodies in HIV-1 carrier sera. Microbiol. Immunol. 39:775-785.
17. McLain, L., C. Porta, G. P. Lomonossoff, Z. Durrani, and N. J. Dimmock. 1995. Human immunodeficiency virus type 1-neutralizing antibodies raised to a glycoprotein 41 peptide expressed on the surface of a plant virus. AIDS Res. Hum. Retroviruses 11:327-334.
18. Mohammed, K., and A. Esen. 1989. A blocking agent and a blocking step are not needed in ELISA, immunostaining dot-blots and Western blots. J. Immunol. Methods 117:141-145.
19. Muster, T., B. Ferko, A. Klima, M. Purtscher, A. Trkola, P. Schulz, A. Grassauer, O. G. Engelhardt, A. Garcia-Sastre, P. Palese, and H. Katinger. 1995. Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virus. J. Virol. 69:6678-6686.
20. Muster, T., F. Steindl, M. Purtscher, A. Trkola, A. Klima, G. Himmler, F. Ruker, and H. Katinger. 1993. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67:6642-6647.
21. Narwa, R., P. Roques, C. Courpotin, F. Parnet-Mathieu, F. Boussin, A. Roane, D. Marcé, G. Lasfargues, and D. Dormont. 1996. Characterization of human immunodeficiency virus type 1 p17 matrix protein motifs associated with mother-to-child transmission. J. Virol. 70:4474-4483.
22. Naylor, P. H., C. W. Naylor, M. Badamchian, S. Wada, A. L. Goldstein, S.-S. Wang, D. K. Sun, A. H. Thornton, and P. S. Sarin. 1987. Human immunodeficiency virus contains an epitope immunoreactive with thymosin α1 and the 30 amino acid synthetic p17 group-specific antigen peptide HGP-30. Proc. Natl. Acad. Sci. USA 84:2951-2955.
23. Papsidero, L. D., M. Sheu, and F. W. Ruscetti. 1989. Human immunodeficiency virus type 1-neutralizing monoclonal antibodies which react with p17 core protein: characterization and epitope mapping. J. Virol. 63:267-272.
24. Pincus, S. H., K. G. Messer, D. H. Schwartz, G. K. Lewis, B. S. Graham, W. A. Blattner, and G. Fisher. 1993. Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees. J. Clin. Invest. 91:1987-1996.
25. Sattentau, Q. J., S. Zolla-Pazner, and P. Poignard. 1995. Epitope exposure on functional, oligomeric HIV-1 gp41 molecules. Virology 206:713-717.
26. gag: identification of epitopes exposed at the surfaces of infected cells. J. Virol. 65:4798-4804.
27. Vella, C., M. Ferguson, G. Dunn, R. Meloen, H. Langedijk, D. Evans, and P. D. Minor. 1993. Characterization and primary structure of a human immunodeficiency virus type 1 (HIV-1) neutralization domain as presented by a poliovirus type 1/HIV-1 chimera. J. Gen. Virol. 74:2603-2607.
28. Vella, C., P. D. Minor, I. V. D. Weller, O. Jenkins, D. Evans, and J. Almond. 1991. Recognition of poliovirus/HIV chimaeras by antisera from individuals with HIV infection. AIDS 5:425-430.
29. Weiss, R. A. 1993. How does HIV cause AIDS? Science 260:1273-1279.